We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Radcal IBA  Group

Download Mobile App




Restriction Spectrum MRI Technique Improves Diagnosis of Prostate Cancer

By HospiMedica International staff writers
Posted on 21 Jan 2015
New magnetic resonance imaging (MRI) technology could soon translate into more effective diagnoses and less invasive interventions for prostate cancer.

Investigators have recently reported on the innovative imaging technique, which measurably improves upon current prostate imaging, and may have significant implications for how patients with prostate cancer are ultimately treated.

Prostate cancer was the leading cause of newly diagnosed cancers in men and the second leading cause of cancer death in men in 2014. More...
The group of scientists and physicians, from the University of California (UC), San Diego School of Medicine (USA), with colleagues at University of California, Los Angeles (UCLA; USA), published their findings in the January 6, 2015, issue of the journal Prostate Cancer and Prostatic Disease. “This new approach is a more reliable imaging technique for localizing tumors. It provides a better target for biopsies, especially for smaller tumors,” said Rebecca Rakow-Penner, MD, PhD, a research resident in the department of radiology and the study’s first author.

The technique is also beneficial in surgical planning and image staging, according to David S. Karow, MD, PhD, assistant professor of radiology at UC San Diego, and the study’s corresponding author. “Doctors at UC San Diego and UCLA now have a noninvasive imaging method to more accurately assess the local extent of the tumor and possibly predict the grade of the tumor, which can help them more precisely and effectively determine appropriate treatment.”

The current standard of care for detecting and diagnosing prostate cancer is contrast-enhanced magnetic resonance imaging (MRI), which involves intravenously injecting patients with a contrast agent to highlight blood flow. Greater blood flow is often a requirement of growing cancer cells. When compared to surrounding healthy tissues, it is hoped that contrast-enhanced MRI scans will reveal the shape and composition of any tumors present.

But many tumors do not significantly differ from surrounding healthy tissues with contrast enhanced MRI and so evade easy detection. An imaging technique called diffusion MRI measures the diffusion of water and has been a standard imaging technique in the brain and an emerging technique in the prostate. Cancer tissues are denser than healthy tissues and typically limit the amount and mobility of water within them. However, diffusion MRI suffers from magnetic field artifacts that can distort the actual location of tumors by as much as 1.2 cm—a substantial distance when surgeons are trying, for instance, to evaluate whether a tumor extends beyond the prostate and into adjacent nerve bundles.

The new imaging strategy in the study is called restriction spectrum imaging-MRI (RSI-MRI). It corrects for magnetic field distortions and focuses upon water diffusion within tumor cells. By doing both, the ability of imaging to accurately plot a tumor’s location is increased and there is a more refined sense of the tumor’s extent, according to Nathan White, PhD, assistant project scientist at UC San Diego, study coauthor, and co-inventor of the RSI-MRI technique.

In a related study to be published in the journal Frontiers in Oncology, the same researchers reported that RSI-MRI appears to predict tumor grade. Higher grade tumors correlate with higher restricted water volume in the cancer cells’ large nuclei. “Prostate cancer can often be an indolent disease, where a patient may only require surveillance rather than aggressive surgery,” noted coauthor Christopher J. Kane, MD, professor of urology at UC San Diego.

“If by imaging we could predict the tumor grade,” added Robert Reiter, MD, professor of urology at UCLA, “we may be able to spare some patients from prostate resection and monitor their cancer with imaging.”

Related Links:

University of California, San Diego
University of California, Los Angeles



Platinum Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Gold Member
Temperature Monitor
ThermoScan Temperature Monitoring Unit
Radiology System
Riviera SPV AT
PACS Workstation
PaxeraView PRO
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: Professor Bumsoo Han and postdoctoral researcher Sae Rome Choi of Illinois co-authored a study on using DNA origami to enhance imaging of dense pancreatic tissue (Photo courtesy of Fred Zwicky/University of Illinois Urbana-Champaign)

DNA Origami Improves Imaging of Dense Pancreatic Tissue for Cancer Detection and Treatment

One of the challenges of fighting pancreatic cancer is finding ways to penetrate the organ’s dense tissue to define the margins between malignant and normal tissue. Now, a new study uses DNA origami structures... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.